What Lonza’s three-month tox supply and six-month IND claim actually covers
Wholesale Peptide Wholesale Enkephalin The claim is narrower than the headline. The accelerated biologics timeline rests on a specific material choice and a specific starting point, and both are footnoted on the pages that carry the numbers.
The bispecific programme page states “3 months to tox material supply” and “DNA to IND in as little as 6 months,” with the six-month footnote reading “Based on the use of pool material. From DNA transfection to delivery of IND-enabling CMC modules. Typical timelines. Subject to agreement with regulatory authorities” (the bispecific programme page). The same page offers an eight-month pathway footnoted “Based on the use of clonal material,” so the faster number depends on earlier-stage pool material rather than a clonal line (the clonal-material alternative).
The mAb programme carries the same structure at shorter intervals: “2 months to tox drug substance,” “3 months to tox drug product,” and DNA-to-IND in as little as 6 months on pool material, with an 8-month alternative on clonal material (Lonza’s mAb programme). The overview page adds an eligibility qualifier, piav txog tshuaj toxicology 'muaj nyob rau hauv ob lub hlis rau cov kev pab cuam tsim nyog' (kev tshuaj xyuas DNA-to-IND programme).
Lonza tus kheej piav txog kev nrawm ua haujlwm yog kev ua haujlwm sib npaug es tsis yog kev txo sijhawm: kev tsim kho tshuaj xyuas thaum ntxov, kev tsim txheej txheem 'tsim rau kev ruaj khov thiab scalability',thiab kev npaj tswj hwm tsim los ntawm thawj zaug (Lonza tus kheej piav txog kev nrawm ua haujlwm li cas). Lonza qhov piav qhia rau rau lub hlis qhia txog kev xaiv ntawm rau thiab yim lub hlis raws li lub hom phiaj molecule thiab kev loj hlob (Lonza qhov piav qhia rau rau lub hlis).
Tus neeg tsim nyog txav tus naj npawb 33%. Tus neeg yuav khoom uas hais rau rau lub hlis tsis muaj cov lus piav qhia txog cov khoom siv pas dej yog hais txog ib qho kev pab cuam txawv ntawm qhov piav qhia.
Why a biologics platform timeline cannot be copied onto a peptide program
Q 6000 h, o 70 v, and notes that inefficient coupling, k. e 100 amino acids, v (e.g., deletion and truncation), t (s).
h. u- a, with hindered Fmoc removal and acylation and truncated or gapped byproducts that are difficult to separate from the target; aggregation-prone motifs include runs of β-methyl residues, alternating hydrophobic and bulky residues, and high glycine content (the peptide literature’s definition of a difficult sequence).
Purity data alone will not reveal all of it. In difficult-sequence syntheses, byproducts lacking internal residues, truncated peptides and Fmoc-retaining peptides were detectable only by ESI-MS/MS and MALDI-TOF, and several sequences yielded only trace target under a standard schedule (MS/MS detection of sequence-related byproducts).
The arithmetic is the argument. At 99.0% per-step success, a 40-residue chain leaves roughly two-thirds of the material full-length before purification; at 99.8%, roughly nine-tenths at 50 residues. I, b.
What sequence confirmation must prove before downstream data is trusted
Sequence confirmation is the gate that validates every later number. d, a.
i,m, where relevant, c, a, l, e, LC-MS, peptide mapping, n (d). a.
ICH Q6B’s structure-confirmation logic sets the same expectation for sequence determination “to the extent possible,” listing amino acid composition, terminal sequence analysis, peptide mapping by HPLC and mass spectrometry, with validated peptide mapping “frequently used to confirm desired product structure for lot release purposes” (ICH Q6B’s structure-confirmation logic). Q6B also notes that synthetic peptides fall outside its scope, so the EMA document is the more specific authority for a chemically synthesized molecule.
Neither document supplies a numeric identity threshold, because ICH Q6B’s definition of a specification makes acceptance criteria “proposed and justified by the manufacturer and approved by regulatory authorities,” with purity acknowledged as method-dependent (ICH Q6B’s definition of a specification).
Kev huv si, tus kheej, content and assay answer four different questions. A single HPLC percentage is a purity figure. Identity needs orthogonal confirmation, content or net peptide Mans Peptide requires its own determination, and assay suitability depends on a reference standard. A proposal that offers one certificate number as proof of all four has answered one question.
The evidence request is concrete: the sequence version under test, the orthogonal pair used at release, and the lot-level data showing both methods agree.
What a defensible impurity profile contains at toxicology stage
Peptide impurity profiling runs on thresholds that differ from the small-molecule defaults, and the difference is large enough to change a specification.
The EMA’s synthetic-peptide guideline, in force since June 2026, states that synthetic peptides are fully or partially excluded from ICH Q3A/B and that, per the Ph. Eur. general monograph “Substances for Pharmaceutical Use” (2034), cov impurities uas cuam tshuam txog peptide yuav tsum tau tshaj tawm saum toj no 0.1%, tau txheeb xyuas saum toj no 0.5% thiab tau piav qhia saum toj no 1.0% (d, in force since June 2026). Where co-eluting impurities appear as one peak, the 1.0% qualification threshold applies unless otherwise justified.
ICH Q3A(R2) sets the small-molecule defaults at 0.05% reporting, 0.10% identification and 0.15% qualification for a maximum daily dose up to 2 g/day, and its preamble lists peptide products among those not covered (ICH Q3A(R2)). Applying those numbers to a peptide is a scope error in the buyer’s favor, since they are tighter than the peptide thresholds.
The EMA guideline’s impurity taxonomy separates peptide-related impurities, which are structural elements of the sequence, from non-peptide impurities such as process reagents, residual solvents and elemental impurities. Peptide-related sources include starting-material defects (incorrect enantiomers and diastereomers, wrong amino acids, β-Ala residues, dipeptides) and process formation (epimerisation stereoisomers, deletion sequences, truncations from capping) (the EMA guideline’s impurity taxonomy).
A profile is only as good as the method behind it. ICH Q2(R2)’s validation characteristics require a quantitative HPLC purity or impurity procedure to address specificity and selectivity, including spiking with known impurities or orthogonal comparison and forced degradation where needed, a calibration model with at least five points plus quantitation and detection limits, o, repeatability, intermediate precision and robustness, and the guideline sets no universal numeric acceptance criteria (ICH Q2(R2)’s validation characteristics).
Co-eluting peaks hide the impurity you most need to see. When two peptide-related impurities resolve as one peak, the EMA guideline applies the 1.0% qualification threshold to the combination unless justified. Ask which peaks in the profile are unresolved combinations and what orthogonal method was used to characterize them.
FDA withdrew its May 2021 general synthetic-peptide ANDA guidance in July 2026. Evaluate current relevant product-specific Peptide Factory Manufacturer drafts or final guidance and their status; historical 0.10%/0.5% criteria are not universal current limits.
What evidence shows a peptide process is scalable, not just reproducible at one scale
Peptide scale-up from mg to kg is proven by a scale-effect study, not by a successful small-batch run. The distinction matters because a process that works at 0.1 mmol tells you nothing about a 6000 L reactor.
ICH Q11’s position on scale effects is that a small-scale model “should account for scale effects and be representative of the proposed commercial process,” that scaling factors should be included for steps intended to span multiple operational scales when the step is scale dependent, and that small-scale data can reduce reliance on commercial-scale validation batches only once the model is shown scalable (ICH Q11’s position on scale effects).
Two published campaigns show what real production-scale peptide data look like. A published kilogram-scale tirzepatide campaign, a 39-residue peptide made by hybrid SPPS/LPPS with continuous manufacturing, reported approximately 81% overall activity yield with 8.71 kg isolated and crude purity around 90% by HPLC (a published kilogram-scale tirzepatide campaign). A matched small- versus production-scale comparison of liraglutide at 0.1 mmol and 25 mmol in a 3 L vessel gave 77–78% crude purity at production scale, matching wash-based results at research and production scale, with model crude purities around 75–84% (a matched small- versus production-scale comparison).
Per-step stereochemical fidelity does not by itself establish total epimer content in the isolated peptide. Measure relevant stereoisomeric impurities and distinguish analytical thresholds from product-specific acceptance criteria. Peptide Research
Request the scale-effect study, not the scale-up promise. The document to ask for is a comparison of at least two operational scales of the same process, with scaling factors stated for each scale-dependent step and impurity profiles compared side by side. I.
b, so treat any proposal that offers one as unsupported until the underlying data is shown.
How we apply this at MOL Changes, the publisher of this guide. q, h. o; you still have to request the per-scale data and judge it yourself, n, t.
Which release tests and records are non-negotiable, and what a CoA must carry
a. u, b, and justified alternative methods may have different timelines.
The records layer is where proposals most often thin out. The audit-trail requirement in 21 CFR 11.10(e) calls for “secure, tsim los ntawm computer, time-stamped audit trails” that record operator entries and actions creating, hloov lossis tshem tawm cov ntaub ntawv hluav taws xob, with changes not obscuring previously recorded information and the trail retained at least as long as the subject records and available for agency review (the audit-trail requirement in 21 CFR 11.10(e)). MHRA’s ALCOA expectations define data as attributable, nyeem tau yooj yim, tam sim no, qub thiab raug, with complete, sib haum xeeb, enduring and available added, and require that audit trails identified by risk assessment be switched on, that users cannot amend or disable them, and that an administrator override itself be recorded (MHRA’s ALCOA expectations). Peptide Factory Supplier
The IND CMC requirement in 21 CFR 312.23(a)(7) sets what the package must ultimately support: sufficient information “to assure the proper identification, quality, purity, and strength of the investigational drug,” with emphasis in an initial Phase 1 submission on identification and control of raw materials and the new drug substance, final specifications not expected until the end of investigation, and information amendments required as scale changes from pilot to larger scale (the IND CMC requirement in 21 CFR 312.23(a)(7)).
A connected data package, tsis yog daim ntawv pov thawj. The CoA should carry the sequence version tested, any modification site, the counterion form, the method identifier behind each result, and the lot number, and it should be traceable to the chromatograms and mass spectra that produced it. A summary certificate without the underlying records cannot be reconstructed, and MHRA’s guidance states that paper copies of dynamic electronic data cannot be considered raw data.
How peptide CRO selection turns a proposal into per-gate evidence requests
Peptide CRO selection reduces to one test: for each gate, does the proposal carry evidence you can inspect, or only a number you can quote? The four gates give you a fixed set of questions that applies to any supplier.
|
Gate |
Cov pov thawj thov |
Standard it answers to |
|---|---|---|
|
Sequence confirmation |
Sequence version under test, two orthogonal identification methods, lot-level agreement between them |
EMA synthetic-peptide guideline; ICH Q6B |
|
Impurity profiling |
Peptide-related impurity list with thresholds applied, unresolved-peak treatment, validated method with forced degradation |
EMA guideline (0.1/0.5/1.0%); ICH Q2(R2) |
|
Scale-up |
Two-scale comparison of the same process, scaling factors for scale-dependent steps, impurity profiles at both scales |
ICH Q11 |
|
Release testing |
USP <71> thiab <85> cov txheej txheem nrog cov ntaub ntawv incubation thiab inhibition/enhancement, audit trails enabled, raw data retrievable |
USP <71>/<85>; 21 CFR Part 11; MHRA ALCOA |
Muaj peb yam cuam tshuam rau cov nyeem ntawv sib txawv. Tus neeg yuav khoom txhawb nqa yuav tsum saib qhov rooj ploj ua kev pheej hmoo hauv daim ntawv teev sijhawm, tsis yog qhov tsis muaj ntaub ntawv, vim txhua qhov rooj uas tsis ua tiav lig yuav siv nyiaj ntau dua lub sijhawm uas nws tau cawm. CRO yuav tsum cia siab rau qhov kev thov thiab npaj kev sib piv ob theem ua ntej theem kev thov. Tus neeg tshuaj xyuas kev xa ntawv yuav tsum nyeem qhov impurity section rau cov threshold tiag tiag siv, vim peptide dossier uas tsim los ntawm Q3A lej tau ua yuam kev rau nws qhov kev qhia.
Txoj cai txiav txim yog ib leeg thiab muaj nqis: if any one of the four gates is missing from the proposal and the supplier will not commit to supplying the evidence before contract signature, the timeline is not a commitment and should not enter your filing plan.
Xaus lus
Lonza’s three-month tox-supply and six-month IND figures are real, footnoted and specific to a biologics platform operating on pool material with a defined starting point. They do not describe a peptide program, and the peptide literature explains why: sub-100% per-coupling yield, sequence-dependent aggregation, and byproducts that HPLC alone will not reveal.
The four gates hold regardless of which supplier you are evaluating. Sequence confirmation must be orthogonal and lot-level. Impurity profiling must apply the peptide thresholds of 0.1% reporting, 0.5% identification and 1.0% qualification, with unresolved peaks treated as combinations. Scale-up must rest on a two-scale comparison with stated scaling factors. Release testing must carry the 14-day sterility incubation, the endotoxin inhibition/enhancement data, and audit trails that satisfy 21 CFR 11.10(e) and MHRA ALCOA.
The earned takeaway is that speed and readiness are different claims, and only one of them is transferable between modalities. The next step is to take the proposal in front of you and mark which of the four gates it answers with evidence you can open. Where a gate is blank, that is the question to send back before signature.
Publisher disclosure: MOL Changes supplies peptide services and has a commercial interest in this topic. Cov kev pabcuam thiab cov lus qhia txog peev xwm yog cov lus thov ntawm cov neeg muab khoom; Kev muaj thiab kev ua tau zoo rau ib qho qauv tshwj xeeb yuav tsum muaj pov thawj tshwj xeeb rau qhov project.
